the saturation model and the limits of

androgen-dependent growth. Eur Urol 2009;

55:

310.

26. Khera M, Bhattacharya RK, Blick G et al:

Changes

in

prostate

specific

antigen

in

hypogonadal men after 12 months of testos-

terone replacement therapy: support for the

prostate saturation theory. J Urol 2011;

186:

1005.

27. Morgentaler A, Benesh JA, Denes BS et al:

Factors influencing prostate-specific antigen

response among men treated with testosterone

therapy for 6 months. J Sex Med 2014;

11:

2818.

28. Rastrelli G, Corona G, Vignozzi L et al: Serum

PSA as a predictor of testosterone deficiency.

J Sex Med 2013;

10:

2518.

29. Song W and Khera M: Physiological normal

levels of androgen inhibit proliferation of pros-

tate cancer cells in vitro. Asian J Androl 2014;

16:

864.

1276

TESTOSTERONE THERAPY AFTER RADIATION THERAPY FOR PROSTATE CANCER